Valensi, Paul
Funding for this research was provided by:
abbott pharmaceuticals
Article History
Received: 24 June 2021
Accepted: 27 July 2021
First Online: 19 August 2021
Declarations
:
: Not applicable.
: Not applicable.
: Paul Valensi discloses the following potential conflicts of interest: lectures for Abbott, AstraZeneca, Bayer, Lilly, Hikma Pharmaceuticals, Merck Sharp & Dohme, Novo Nordisk, Novartis, Pfizer, Sanofi; research grants from Abbott, Bristol-Myers-Squibb–AstraZeneca, Novo Nordisk; participation in expert committees for AstraZeneca, Boehringer Ingelheim, Daiichi Sankyo, Lilly, Novo Nordisk, Sanofi, Servier, Stendo.